AzTrials
AzTrials

Vascular Closure DeviceNCT07862309

Safety and Effectiveness Clinical Study of Novelrad Vascular Closure System (NVCS)

A study testing Novelrad Vascular Closure System (NVCS) in people with Vascular Closure Device and Femoral Arteriotomy Closure, run by Novelrad Ltd..

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study evaluates the safety and effectiveness of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Novelrad Vascular Closure System (NVCS)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
65 participants
Where
No sites listed yet
Study dates
Nov 2026to Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject is ≥18 years old.
  • Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the common femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
  • Subject has common femoral artery diameter ≥ 6 mm and accepted calcification status as evaluated on pre-procedural CT angiography by the investigator and by the Sponsor, if requested.
  • Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery.
  • Understand and sign the study specific written informed consent form.
  • Able and willing to fulfill the follow-up requirements.

Who cannot join

  • Baseline Exclusions:
  • Known to be pregnant or lactating.
  • Immunocompromised or with pre-existing autoimmune disease.
  • Systemic infection or a local infection at or near the access site.
  • Significant anemia (Hgb < 9 g/dL hematocrit <30%).
  • Morbidly obese or cachectic (BMI >40 kg/m2 or <20kg/m2).
Show all 50Show fewer
  • Known bleeding disorders including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability/thrombophilia.
  • Known allergy to any device component.
  • Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
  • Common femoral artery with calcification status, as determined by baseline CTA, precluding safe access in the opinion of the investigator (or the Sponsor, if requested) or severe peripheral vascular disease as evidenced by severe claudication when ambulating < 30 meter, weak or absent pulses in the affected limb or ABI < 0.5 at rest.
  • Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
  • Prior target artery closure with any closure device at the access site < 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
  • Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
  • Undergoing therapeutic thrombolysis.
  • Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR >1.8 at the time of the index procedure.
  • Subject unable to be adequately anti-coagulated for the index procedure.
  • Subjects who are unable to ambulate at baseline and/or are confined to a wheelchair or bed.
  • ST-elevation MI within 45 days prior to index procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
  • NYHA class IV heart failure.
  • Left ventricular ejection fraction <20%.
  • Unilateral or bilateral lower extremity amputation.
  • Renal insufficiency (serum creatinine >2.5 mg/dl) or on dialysis therapy, or after renal transplant.
  • Existing nerve damage in the NVCS treated leg.
  • Further planned endovascular catheterization procedure within the next 30 days.
  • Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
  • Subject cannot adhere to or complete the investigational Clinical Investigation Plan for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
  • Common femoral artery <6mm or >50% diameter femoral stenosis by baseline CTA
  • Planned anticoagulation therapy post-index procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the index procedure.
  • Known severe allergy to contrast reagent that cannot be managed with premedication.
  • Connective tissue disease (e.g., Marfan's Syndrome).
  • Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the index procedure.
  • Subject is mentally incompetent or a prisoner.
  • Planned antegrade puncture during the index procedure.
  • Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCD (if the >50% stenosis is not considered preventing the use of NVCD, it must be recorded as such).
  • Intra-Procedural Exclusions:
  • On baseline Duplex US the Common femoral artery <6mm or >50% stenosis of the femoral artery.
  • Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCD (if the >50% stenosis is not considered preventing the use of NVCD, it must be recorded as such).
  • Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
  • Common femoral artery suspected to have experienced a back wall puncture or underwent > 2 arterial punctures, during the catheterization procedure.
  • Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators).
  • Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
  • Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
  • Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
  • Planned antegrade puncture during the index procedure.
  • Presence of ipsilateral femoral venous sheath during the interventional procedure.
  • Systolic blood pressure <90 mm Hg just prior to planned vascular closure without the ability to increase it.
  • Planned anticoagulation therapy post-index procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the index procedure.
  • Index procedure planned sheath or interventional device >22 Fr.
  • Evidence of a pre-existing hematoma (> 2 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCD.
  • Imaging (Duplex Ultrasound / Angiography) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Milly Kushnir contact

972-54-6607046

Milly.k@novelrad.com

Dr. Yossi Muncher contact

972-50-8580308

Yossi.m@novelrad.com

About this study

Official title: A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Suture-Mediated Novelrad Vascular Closure System

This study evaluates the safety and effectiveness of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths.

Read the detailed description

The Novelrad Vascular Closure System (NVCS) is an investigational suture mediated vascular closure device intended for use following percutaneous interventional catheterization procedures performed through the common femoral artery using large-bore procedural sheaths. The NVCS is designed to facilitate percutaneous closure of the arteriotomy using a continuous suture technique. The study is being conducted to evaluate the safety and effectiveness of the NVCS in subjects undergoing percutaneous interventional catheterization procedures using large-bore procedural sheaths.

Being tested
Novelrad Vascular Closure System (NVCS)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Novelrad Vascular Closure System (NVCS)Device

    NVCS will be used to close the common femoral artery access site while reducing time-to-hemostasis in subjects who have undergone diagnostic or interventional catheterization procedures using 8-22 French (F) Sheaths.

Study groups in NCT07862309
Study groupRoleWhat they receive
Novelrad Vascular Closure System (NVCS)ExperimentalThe Novelrad Vascular Closure System (NVCS), will be used in subjects who are undergoing diagnostic or interventional catheterization procedures
Receives: Device: Novelrad Vascular Closure System (NVCS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety: Freedom from major complications of the target limb within 30 days following the NVCS and index procedure.

    Assessment of the incidence of protocol defined major complications of the target limb access site through 30 days post NVCS and index procedure as specified in the protocol.

    Measured: Within 30 days post-procedure

  2. Effectiveness: Time to Hemostasis

    TTH is defined as the time elapsed from procedural sheath removal to first observed cessation of common femoral artery bleeding (excluding cutaneous or subcutaneous oozing at access site).

    Measured: Periprocedural

Secondary outcomes (5)

  1. Safety: Freedom from minor complications at the target limb access site

    Assessment of the incidence of minor complications of the target limb access site as specified in the protocol.

    Measured: Within 30 days post procedure

  2. Effectiveness: Technical Success

    Defined as achievement of hemostasis with the NVCS without the use of unplanned endovascular or surgical intervention

    Measured: Periprocedural

  3. Effectiveness: Treatment Success

    Defined as technical success and freedom from major complications through 30 days follow-up

    Measured: Within 30 days post procedure

  4. Effectiveness: Time to Ambulation

    Defined as the elapsed time between last procedural sheath removal and when ambulation is achieved (subject is standing and walking at least 6-meters without bleeding).

    Measured: At least 6 hours after sheath removal

  5. Effectiveness: Time-to-discharge eligibility

    The Time to discharge eligibility is defined as the time following the index procedural sheath removal until the subject is considered eligible for discharge based solely on the access site criteria: (1) successful completion of ambulation test, (2) subject's access site with no bleeding (mild oozing is allowed), and (3) the duplex ultrasound of up to 48 hours ("prior to discharge duplex ") demonstrated acceptable status of access site as judged by the investigator (or designee).

    Measured: Within 48 hours after the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionMar 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
65 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07862309
Sponsor's protocol ID
NVCS-CLN-016
Status last verified
Oct 2026
First submitted
1 Oct 2026
Last updated
7 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Novelrad Vascular Closure System (NVCS) in people with Vascular Closure Device and Femoral Arteriotomy Closure, run by Novelrad Ltd..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 50 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Milly Kushnir (972-54-6607046, Milly.k@novelrad.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: Freedom from major complications of the target limb within 30 days following the NVCS and index procedure. (time frame: Within 30 days post-procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07862309.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in